Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Trulicity Shows Superiority in Reducing Weight, A1C

Lilly’s diabetes drug Trulicity hit the mark in a late-stage trial showing higher doses of the medication significantly reduced A1C from baseline versus the product’s approved once-weekly usage.

Read More »

Novo Nordisk Q1 2019 profit tops forecast

Danish drugmaker Novo Nordisk beat first-quarter 2019 operating profit forecasts, helped by higher sales of the company’s biggest new drug hope, a treatment for type 2 diabetes.

Read More »

Gelesis Granted FDA Clearance to Market PLENITY™ — a New Prescription Aid in Weight Management

Gelesis announced that the United States Food and Drug Administration cleared the biotechnology company’s lead product candidate Plenity (Gelesis100) as an aid in weight management in adults with a Body Mass Index (BMI) of 25–40 kg/m2, when used in conjunction with diet and exercise.

Read More »

Year-End Research Advances Approaches, Both Genetic and Device-Oriented, to Treat Obesity

A 2017 study found that more than 700 million adults and children worldwide are obese, calling it a “rising pandemic.”

Read More »

Tivity Health to buy Nutrisystem for $1.4 billion

Tivity Health Inc. said the company would acquire Nutrisystem Inc. in a cash-and-stock deal that values the weight management product developer at $1.4 billion.

Read More »

A Single Gene to Rule Them All: A Single Gene Might Control Obesity

Researchers at Flinders University in Australia – working with mice – removed a single gene known as RCAN1 and then fed them a variety of diets, including a high-fat diet. The mice did not gain weight, even after dramatically overeating high-fat foods over several weeks.

Read More »

Alkermes schizophrenia drug keeps weight gain side effect in check

Alkermes Plc’s schizophrenia drug ALKS 3831 met the main goal of keeping in check a common side effect of antipsychotic medicines – weight gain – taking the company one step closer to a marketing approval for the experimental treatment.

Read More »

Adults need a regular bedtime, too

Adults who have a regular bedtime are likely to weigh less than those who do not, to have lower blood sugar and to face a lower risk of heart disease and diabetes, according to a U.S. study.

Read More »

Moderate ‘bad cholesterol’ levels tied to early death for healthy people

Healthy adults who do not keep their LDL-C, or “bad cholesterol,” in check are more likely to die prematurely from cardiovascular disease than peers with lower cholesterol levels, a U.S. study suggests.

Read More »

Novo Nordisk’s Semaglutide Hits Mark in T2D Trial

Novo Nordisk revealed that oral semaglutide achieved positive results in the PIONEER 5 study for the reduction of blood sugar levels and weight in adults with type 2 diabetes.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!

Subscribe

Ad Right Bottom